Pictet Generics P Dist GBP
Overview
| Fund manager's initial charge | 5.00% |
|---|---|
| HL initial saving | 5.00% |
| Net initial charge | 0.00% |
| Dealing charge | Free |
| Fund manager's annual charge | 1.60% |
| Performance charges | No |
| Total Expense Ratio | 2.00% |
| HL annual saving | 0.00% 2 |
| Platform fee | Free |
| Launch date | 01-07-2004 |
| Launch price | $100.00 |
| Sector | Offshore |
| Fund size | $394.00 million |
| Number of holdings | 30 |
| Fund type | SICAV |
| Type of units | Income |
Please read the Simplified Prospectus/Key Investor Information Document in addition to the information above.
Invest online now
Before you invest please read the key features and Simplified Prospectus/Key Investor Information Document for more details.
HL research - our view on this fund
About the Fund Manager
Paulina Niewiadomska
Located in: London
Paulina Niewiadomska, CFA joined Sectoral Asset Management (Sectoral) in 2006. With an M.Sc. in molecular biology and an international MBA in finance she had spent three years on the sell-side covering the Canadian healthcare sector prior to joining Sectoral. Upon joining the firm, she started covering the generic and specialty pharmaceutical companies and integrated in the Pictet-Generics fund management team. In 2009, she was promoted to Senior Financial Analyst and took on additional responsibilities within the Pictet-Generics fund management team. With effect April 1, 2011, she was named Portfolio Manager and will become the lead manager of the Pictet-Generics fund. She continues to assume her analytical coverage and is working closely with Michael Sjöström, CFA, CIO of Sectoral, who acts as her backup on the strategy.
Income details
| Running yield | N/a |
|---|---|
| Income paid | Annually |
| Type of payment | No income |
All yields are variable and not guaranteed. There is currently no yield information available for this fund.
Distribution dates
| Ex-dividend date | 02 December 2012 |
|---|---|
| Payment date 4 | 03 December 2012 |
Top 10 holdings
| Aspen Pharmacare Holdings | 6.52% |
|---|---|
| Perrigo Co. | 6.37% |
| Hikma Pharmaceuticals | 6.31% |
| Mylan | 5.60% |
| Sawai Pharmaceutical Co. | 4.40% |
| Stada Arzneimittel AG | 3.99% |
| Hospira | 3.93% |
| OJSC Pharmstandard | 3.91% |
| Lupin (Deutsche Bk)Lepo Wts 200217 | 3.87% |
| CFR Corporacion Farmaceutica Recalcine | 3.73% |
Top 10 sectors
| Pharmaceuticals & Biotechnology | 77.12% |
|---|---|
| Non-Classified | 22.22% |
| Cash and Equiv. | 0.65% |
Top 10 countries
| United States | 22.26% |
|---|---|
| Germany | 12.98% |
| Japan | 10.97% |
| Non-Classified | 9.83% |
| United Kingdom | 9.71% |
| South Africa | 6.52% |
| Russian Federation | 3.91% |
| Chile | 3.73% |
| Switzerland | 3.32% |
| South Korea | 3.31% |
Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties.
2 Annual saving is not available in the SIPP or Junior ISA.
4 If you elect to receive the income from a Vantage ISA, Fund or Share Account, we will collect any dividends for you and then pay them directly into your bank account within the first 10 working days of the following month.
Prices as at 09-02-2012. Data as at 31/12/2011.
